Investor mix
22 investors on record; lead investors include Frazier Healthcare Partners, Qiming; 5 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 12 | 55% |
| Private equity | 6 | 27% |
| Other / undisclosed | 4 | 18% |
Immune modulatory biologic therapeutics for cancer, Atherosclerosis, fibrosis and inflammatory bowel disease
22 investors on record; lead investors include Frazier Healthcare Partners, Qiming; 5 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 12 | 55% |
| Private equity | 6 | 27% |
| Other / undisclosed | 4 | 18% |